Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 390 | 34 | 354 |
| Samples | 192 | 16 | 175 |
| Peptides | 165 | 19 | 150 |
Function
PTGES3L-AARSD1 · PTGES3L-AARSD1 readthrough
This locus represents naturally occurring readthrough transcription between the neighboring PTGES3L (prostaglandin E synthase 3 (cytosolic)-like) and AARSD1(alanyl-tRNA synthetase domain containing 1) genes on chromosome 17. The readthrough transcript encodes a fusion protein that shares sequence identity with each individual gene product. [provided by RefSeq, May 2012].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 152 amino-acid changes on canonical ENST00000360221 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PTGES3L-AARSD1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PTGES3L-AARSD1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Mesothelioma | 0/62 0% | 3/165 2% |
| Endometrial Carcinoma | 1/42 2% | 7/612 1% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Melanoma | 0/210 0% | 23/1899 1% |
| Bladder Carcinoma | 0/58 0% | 11/956 1% |
| Colorectal Carcinoma | 3/143 2% | 32/3239 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Gastric Carcinoma | 0/74 0% | 13/1809 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 5/810 1% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 8/1390 1% |
| Rhabdomyosarcoma | 1/33 3% | 0/171 0% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Other Solid Cancers | 0/94 0% | 7/1515 0% |
| Neuroendocrine Tumour | 0/154 0% | 3/577 1% |
| Hepatocellular Carcinoma | 1/46 2% | 8/2210 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| Ovarian Carcinoma | 1/109 1% | 3/998 0% |
| Head and Neck Carcinoma | 0/85 0% | 6/1574 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 5/1592 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 8/2550 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Neuroblastoma | 1/87 1% | 2/1331 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Breast Carcinoma | 1/144 1% | 5/3264 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 4/2534 0% |
| Other Sarcomas | 1/69 1% | 0/699 0% |
Mutation Distribution
Where PTGES3L-AARSD1 is mutated · all tissues, split by cell line vs tissue
How many mutations in PTGES3L-AARSD1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
Mutations
All 390 mutations in PTGES3L-AARSD1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|